Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
01 2021
Historique:
received: 12 07 2020
revised: 27 10 2020
accepted: 04 11 2020
pubmed: 11 12 2020
medline: 15 1 2021
entrez: 10 12 2020
Statut: ppublish

Résumé

Countries have restricted international arrivals to delay the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These measures carry a high economic and social cost, and might have little effect on COVID-19 epidemics if there are many more cases resulting from local transmission compared with imported cases. Our study aims to investigate the extent to which imported cases contribute to local transmission under different epidemic conditions. To inform decisions about international travel restrictions, we calculated the ratio of expected COVID-19 cases from international travel (assuming no travel restrictions) to expected cases arising from internal spread, expressed as a proportion, on an average day in May and September, 2020, in each country. COVID-19 prevalence and incidence were estimated using a modelling framework that adjusts reported cases for under-ascertainment and asymptomatic infections. We considered different travel scenarios for May and September, 2020: an upper bound with estimated travel volumes at the same levels as May and September, 2019, and a lower bound with estimated travel volumes adjusted downwards according to expected reductions in May and September, 2020. Results were interpreted in the context of local epidemic growth rates. In May, 2020, imported cases are likely to have accounted for a high proportion of total incidence in many countries, contributing more than 10% of total incidence in 102 (95% credible interval 63-129) of 136 countries when assuming no reduction in travel volumes (ie, with 2019 travel volumes) and in 74 countries (33-114) when assuming estimated 2020 travel volumes. Imported cases in September, 2020, would have accounted for no more than 10% of total incidence in 106 (50-140) of 162 countries and less than 1% in 21 countries (4-71) when assuming no reductions in travel volumes. With estimated 2020 travel volumes, imported cases in September, 2020, accounted for no more than 10% of total incidence in 125 countries (65-162) and less than 1% in 44 countries (8-97). Of these 44 countries, 22 (2-61) had epidemic growth rates far from the tipping point of exponential growth, making them the least likely to benefit from travel restrictions. Countries can expect travellers infected with SARS-CoV-2 to arrive in the absence of travel restrictions. Although such restrictions probably contribute to epidemic control in many countries, in others, imported cases are likely to contribute little to local COVID-19 epidemics. Stringent travel restrictions might have little impact on epidemic dynamics except in countries with low COVID-19 incidence and large numbers of arrivals from other countries, or where epidemics are close to tipping points for exponential growth. Countries should consider local COVID-19 incidence, local epidemic growth, and travel volumes before implementing such restrictions. Wellcome Trust, UK Foreign, Commonwealth & Development Office, European Commission, National Institute for Health Research, Medical Research Council, and Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Countries have restricted international arrivals to delay the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These measures carry a high economic and social cost, and might have little effect on COVID-19 epidemics if there are many more cases resulting from local transmission compared with imported cases. Our study aims to investigate the extent to which imported cases contribute to local transmission under different epidemic conditions.
METHODS
To inform decisions about international travel restrictions, we calculated the ratio of expected COVID-19 cases from international travel (assuming no travel restrictions) to expected cases arising from internal spread, expressed as a proportion, on an average day in May and September, 2020, in each country. COVID-19 prevalence and incidence were estimated using a modelling framework that adjusts reported cases for under-ascertainment and asymptomatic infections. We considered different travel scenarios for May and September, 2020: an upper bound with estimated travel volumes at the same levels as May and September, 2019, and a lower bound with estimated travel volumes adjusted downwards according to expected reductions in May and September, 2020. Results were interpreted in the context of local epidemic growth rates.
FINDINGS
In May, 2020, imported cases are likely to have accounted for a high proportion of total incidence in many countries, contributing more than 10% of total incidence in 102 (95% credible interval 63-129) of 136 countries when assuming no reduction in travel volumes (ie, with 2019 travel volumes) and in 74 countries (33-114) when assuming estimated 2020 travel volumes. Imported cases in September, 2020, would have accounted for no more than 10% of total incidence in 106 (50-140) of 162 countries and less than 1% in 21 countries (4-71) when assuming no reductions in travel volumes. With estimated 2020 travel volumes, imported cases in September, 2020, accounted for no more than 10% of total incidence in 125 countries (65-162) and less than 1% in 44 countries (8-97). Of these 44 countries, 22 (2-61) had epidemic growth rates far from the tipping point of exponential growth, making them the least likely to benefit from travel restrictions.
INTERPRETATION
Countries can expect travellers infected with SARS-CoV-2 to arrive in the absence of travel restrictions. Although such restrictions probably contribute to epidemic control in many countries, in others, imported cases are likely to contribute little to local COVID-19 epidemics. Stringent travel restrictions might have little impact on epidemic dynamics except in countries with low COVID-19 incidence and large numbers of arrivals from other countries, or where epidemics are close to tipping points for exponential growth. Countries should consider local COVID-19 incidence, local epidemic growth, and travel volumes before implementing such restrictions.
FUNDING
Wellcome Trust, UK Foreign, Commonwealth & Development Office, European Commission, National Institute for Health Research, Medical Research Council, and Bill & Melinda Gates Foundation.

Identifiants

pubmed: 33301722
pii: S2468-2667(20)30263-2
doi: 10.1016/S2468-2667(20)30263-2
pmc: PMC7801817
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12-e20

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19065
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206250/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 208812/Z/17/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Science. 2020 Jul 17;369(6501):297-301
pubmed: 32471856
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Lancet. 2020 Feb 29;395(10225):664-666
pubmed: 32061311
Epidemics. 2020 Sep;32:100397
pubmed: 32540727
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
BMC Med. 2020 Oct 22;18(1):332
pubmed: 33087179
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7504-7509
pubmed: 32170017
Euro Surveill. 2020 Jan;25(4):
pubmed: 32019667
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
BMJ. 2020 Aug 27;370:m3350
pubmed: 32855153
Lancet Infect Dis. 2020 Aug 4;:
pubmed: 32763195
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634

Auteurs

Timothy W Russell (TW)

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Joseph T Wu (JT)

School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.

Sam Clifford (S)

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.

W John Edmunds (WJ)

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Adam J Kucharski (AJ)

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.

Mark Jit (M)

Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK; School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China. Electronic address: mark.jit@lshtm.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH